Neumora Therapeutics, Inc.(NMRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NMRA Neumora Therapeutics, Inc.

Pre-Mkt 10-19 06:43:59 EDT

0.4738

+0.0468

+10.96%

盘前0.5200

+0.0462+9.75%

06:26 EDT

High0.5062	Low0.4200	Vol3.52M
Open0.4366	D1 Closing0.4270	Amplitude20.19%
Mkt Cap89.07M	Tradable Cap54.96M	Total Shares188.00M
T/O1.69M	T/O Rate3.04%	Tradable Shares116.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NMRA","market":"US","secType":"STK","nameCN":"Neumora Therapeutics, Inc.","latestPrice":0.4738,"timestamp":1792180800000,"preClose":0.427,"halted":0,"volume":3524374,"hourTrading":{"tag":"盘前","latestPrice":0.52,"preClose":0.4738,"latestTime":"06:26 EDT","volume":920,"amount":444.71000480000004,"timestamp":1792405604800,"change":0.0462,"changeRate":0.097509,"amplitude":0.094977},"delay":0,"changeRate":0.10960187353629978,"floatShares":115999999,"shares":188000000,"eps":-1.223678,"marketStatus":"Pre-Mkt","change":0.0468,"latestTime":"10-19 06:43:59 EDT","open":0.4366,"high":0.5062,"low":0.42,"amount":1686262.67969264,"amplitude":0.201874,"askPrice":0.52,"askSize":500,"bidPrice":0.439,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.223678,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1792416600000},"marketStatusCode":1,"adr":0,"listingDate":1694750400000,"exchange":"NASDAQ","adjPreClose":0.4738,"preHourTrading":{"tag":"盘前","latestPrice":0.52,"preClose":0.4738,"latestTime":"06:26 EDT","volume":920,"amount":444.71000480000004,"timestamp":1792405604800,"change":0.0462,"changeRate":0.097509,"amplitude":0.094977},"postHourTrading":{"tag":"盘后","latestPrice":0.4722,"preClose":0.4738,"latestTime":"19:59 EDT","volume":68535,"amount":33627.4258,"timestamp":1792195172644,"change":-0.0016,"changeRate":-0.003377,"amplitude":0.058675},"volumeRatio":1.3811854690242178,"impliedVol":2.3122,"impliedVolPercentile":0.78},"requestUrl":"/m/hq/s/NMRA","defaultTab":"news","newsList":[{"id":"2661780652","title":"ANI Pharma Appoints Henry Gosebruch to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2661780652","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661780652?lang=en_us&edition=fundamental","pubTime":"2026-08-24 18:55","pubTimestamp":1787568930,"startTime":"0","endTime":"0","summary":"ANI Pharma appoints Henry Gosebruch to board of directorsANI Pharmaceuticals appointed Henry Gosebruch to its board, effective Aug. 19, 2026.Gosebruch has been CEO of Lakefront Biotherapeutics NV sinc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL5nczHG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IYH","LU0689626769.HKD","SG9999014013.SGD","LU1718418525.SGD","LU2087621335.USD","AGNG","LU2089283258.USD","IE00B2B36J28.USD","LU0211328371.USD","XLV","ABBV","LU2210150020.SGD","LU1430594728.SGD","FTXH","LU0738911758.USD","MEDX","BK4588","LU0158827948.USD","GLAM","LU0069063385.USD","LU0511384066.AUD","BCDF","LU0314104364.USD","IXJ","NMRA","LU0868494617.USD","ANIP","IE00BBT3K403.USD","JDOC","LU0661504455.SGD","LU1037948897.HKD","NDAQ","PJP","LU0417517546.SGD","LU0395794307.EUR","IE00BN0W2W23.USD","LU2129689514.USD","IE000WAW04H5.SGD","LU1023059063.AUD","PPH","RXL","LU1989772840.SGD","TRUH","BK4585","VHT","IE00BKPKM429.USD","LU0128525929.USD","IE00BSNM7G36.USD","LU1670627923.USD","FHLC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661357215","title":"Top Neumora Executive Makes Notable Move With Insider Stock Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2661357215","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661357215?lang=en_us&edition=fundamental","pubTime":"2026-08-22 10:05","pubTimestamp":1787364307,"startTime":"0","endTime":"0","summary":"New insider activity at Neumora Therapeutics, Inc. ( ($NMRA) ) has taken place on August 21, 2026. Neumora Therapeutics, Inc. reported an insider s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-neumora-executive-makes-notable-move-with-insider-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-neumora-executive-makes-notable-move-with-insider-stock-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661218274","title":"Neumora Chief Operating and Development Officer Aurora Daljit Singh Disposes of USD 135,222.93 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2661218274","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661218274?lang=en_us&edition=fundamental","pubTime":"2026-08-22 07:11","pubTimestamp":1787353889,"startTime":"0","endTime":"0","summary":"Neumora Chief Operating and Development Officer Aurora Daljit Singh disposes of USD 135,222.93 in common sharesNeumora: Chief Operating and Development Officer Aurora Daljit Singh cut direct common st","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL8bswGc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Neumora Chief Operating and Development Officer Aurora Daljit Singh Disposes of USD 135,222.93 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660479679","title":"Neumora Therapeutics COO and Chief Development Officer Aurora Daljit Singh Disposes of 242,773 Common Shares Worth USD 377,639.16","url":"https://stock-news.laohu8.com/highlight/detail?id=2660479679","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660479679?lang=en_us&edition=fundamental","pubTime":"2026-08-20 07:17","pubTimestamp":1787181471,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics COO and Chief Development Officer Aurora Daljit Singh disposes of 242,773 common shares worth USD 377,639.16Neumora Therapeutics Chief Operating and Development Officer Aurora Dal","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL45RSSC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Neumora Therapeutics COO and Chief Development Officer Aurora Daljit Singh Disposes of 242,773 Common Shares Worth USD 377,639.16","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660456490","title":"Neumora Therapeutics, Inc. (NMRA) Receives a Buy from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2660456490","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660456490?lang=en_us&edition=fundamental","pubTime":"2026-08-18 10:25","pubTimestamp":1787019953,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Buy rating on Neumora Therapeutics, Inc. on August 14 and set a price target of $5.00. The company’...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neumora-therapeutics-inc-nmra-receives-a-buy-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neumora-therapeutics-inc-nmra-receives-a-buy-from-rbc-capital-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","LU0708994859.HKD","BK4207","LU0029864427.USD","LU1267930573.SGD","LU0310800379.SGD","GSIB","LU0128525929.USD","NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659917738","title":"Neumora Therapeutics reports Q2 EPS (23c), consensus (24c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659917738","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659917738?lang=en_us&edition=fundamental","pubTime":"2026-08-16 21:42","pubTimestamp":1786887778,"startTime":"0","endTime":"0","summary":"“We delivered another quarter of disciplined execution against our strategic priorities, advancing key programs across our pipeline and positioning...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-reports-q2-eps-23c-consensus-24c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-reports-q2-eps-23c-consensus-24c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659177339","title":"Neumora Therapeutics CEO Paul Berns to switch roles, Joshua Pinto to succeed","url":"https://stock-news.laohu8.com/highlight/detail?id=2659177339","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659177339?lang=en_us&edition=fundamental","pubTime":"2026-08-16 21:42","pubTimestamp":1786887760,"startTime":"0","endTime":"0","summary":"Neumora announced the appointment of Joshua Pinto as president and chief executive officer and a member of the board. Co-founder Paul Berns, will s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-ceo-paul-berns-to-switch-roles-joshua-pinto-to-succeed-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/neumora-therapeutics-ceo-paul-berns-to-switch-roles-joshua-pinto-to-succeed-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659312360","title":"Neumora Therapeutics, Inc. (NMRA) Receives a Rating Update from a Top Analyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2659312360","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659312360?lang=en_us&edition=fundamental","pubTime":"2026-08-15 00:35","pubTimestamp":1786725355,"startTime":"0","endTime":"0","summary":"Needham analyst Ami Fadia reiterated a Buy rating on Neumora Therapeutics, Inc. today and set a price target of $5.00. According to TipRanks, Fadia...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/neumora-therapeutics-inc-nmra-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/neumora-therapeutics-inc-nmra-receives-a-rating-update-from-a-top-analyst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659491401","title":"Neumora Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659491401","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659491401?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:20","pubTimestamp":1786710002,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryNeumora Therapeutics IncNMRA.OQreported a quarterly adjusted loss of 23 cents per share for the quarter ended J","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B0RO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659145476","title":"Neumora Therapeutics Posts Corporate Presentation on Neuroscience Drug Development Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2659145476","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659145476?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:27","pubTimestamp":1786706879,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics posts corporate presentation on neuroscience drug development strategyNeumora outlined a pipeline spanning cardiometabolic, neurodegenerative, neuropsychiatric programs, with mult","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL1SlZ1B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659145782","title":"Neumora Therapeutics Promotes Pinto to CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2659145782","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659145782?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:26","pubTimestamp":1786706760,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics promoted Joshua Pinto to chief executive, about a year after he was named president of the biopharmaceutical company.Pinto succeeds Paul Berns, who will assume the role of executive chairperson of the board.Since joining the company in 2021 as finance chief, Pinto has served in roles of increasing responsibility. His experience in the biotech industry, coupled with his scientific expertise, position him well to lead Neumora, the company said Friday.Neumora also appointed Doron Sagman as its chief medical officer. He brings with him more than two decades of executive leadership experience in clinical development, medical affairs, regulatory strategy and psychiatry.The new appointments came as Neumora narrowed its second-quarter net loss to $43.1 million, or 23 cents a share, from a net loss of $52.7 million, or 33 cents a share, a year earlier.The company said it had $116.8 million in cash and cash equivalents as of June 30, expected to enable the company to fund it","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Neumora Therapeutics Promotes Pinto to CEO","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659459601","title":"Neumora Therapeutics Q2 EPS $(0.23) Beats $(0.24) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659459601","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659459601?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:18","pubTimestamp":1786706323,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 30.3 percent increase over losses of $(0.33) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/61204242/neumora-therapeutics-q2-eps-0-23-beats-0-24-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659297143","title":"Neumora Therapeutics - Appoints Joshua Pinto as President and CEO and Board Member","url":"https://stock-news.laohu8.com/highlight/detail?id=2659297143","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659297143?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA6NC1QP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659143736","title":"Neumora Therapeutics - Q2 2026 Net Loss $43.10 Mln vs $52.70 Mln in Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2659143736","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659143736?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA6NC1QP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NMRA","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659143274","title":"Neumora Therapeutics - Paul L. Berns to Serve as Executive Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2659143274","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659143274?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA6NC1QP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659145881","title":"Press Release: Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659145881","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659145881?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:00","pubTimestamp":1786705200,"startTime":"0","endTime":"0","summary":"president and chief executive officer and a member of the Board of. Directors. Co-founder Paul L. Berns, will serve as Executive Chair.-- Dr. Pinto has made significant contributions to Neumora since. joining in 2021, having served in roles of increasing","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NMRA","BK4132","BK4007","AD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658948005","title":"Neumora Therapeutics Inc Expected to Post a Loss of 24 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2658948005","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658948005?lang=en_us&edition=fundamental","pubTime":"2026-08-12 04:10","pubTimestamp":1786479005,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc <NMRA.OQ> expected to post a loss of24cents a share - Earnings PreviewNeumora Therapeutics IncNMRA.OQNMRA.Ois expected to  show no change in quarterly revenue when it reports ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260811:nL8N44820Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656291399","title":"Neumora Therapeutics Inc Expected to Post a Loss of 24 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2656291399","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656291399?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:26","pubTimestamp":1785529565,"startTime":"0","endTime":"0","summary":"Neumora Therapeutics Inc <NMRA.OQ> expected to post a loss of24cents a share - Earnings PreviewNeumora Therapeutics IncNMRA.OQNMRA.Ois expected to  show no change in quarterly revenue when it reports ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nL8N43X34A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NMRA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654003470","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vericel (VCEL), Sarepta Therapeutics (SRPT) and Neumora Therapeutics, Inc. (NMRA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654003470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654003470?lang=en_us&edition=fundamental","pubTime":"2026-07-28 18:20","pubTimestamp":1785234017,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vericel (VCEL), Sarepta Therapeutics (SRPT) and Neumora Therapeut...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-vericel-vcel-sarepta-therapeutics-srpt-and-neumora-therapeutics-inc-nmra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-vericel-vcel-sarepta-therapeutics-srpt-and-neumora-therapeutics-inc-nmra-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0002141913.USD","BK4588","BK4139","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","BK4137","SRPT","VCEL","LU0029874061.USD","LU0128526141.USD","HCSG","XBI","BK4007","NMRA","IE0009355771.USD","BK4585","XLV","SRPU","IE00BJJMRZ35.SGD","LABU","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654049818","title":"Neumora Therapeutics: Buy Rating Backed by De-Risked NMRA-215 Development and Strengthening NLRP3 Class Thesis","url":"https://stock-news.laohu8.com/highlight/detail?id=2654049818","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654049818?lang=en_us&edition=fundamental","pubTime":"2026-07-27 22:55","pubTimestamp":1785164117,"startTime":"0","endTime":"0","summary":"William Blair analyst Myles Minter has maintained their bullish stance on NMRA stock, giving a Buy rating today. Myles Minter has given his Buy rat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/neumora-therapeutics-buy-rating-backed-by-de-risked-nmra-215-development-and-strengthening-nlrp3-class-thesis-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/neumora-therapeutics-buy-rating-backed-by-de-risked-nmra-215-development-and-strengthening-nlrp3-class-thesis-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NMRA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neumoratx.com","stockEarnings":[{"period":"1week","weight":-0.004},{"period":"1month","weight":-0.3872},{"period":"3month","weight":-0.7057},{"period":"6month","weight":-0.7796},{"period":"1year","weight":-0.7338},{"period":"ytd","weight":-0.7353}],"compareEarnings":[{"period":"1week","weight":-0.0197},{"period":"1month","weight":0.0122},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.1553},{"period":"ytd","weight":0.1193}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.277431},{"month":2,"riseRate":0.666667,"avgChangeRate":0.248427},{"month":3,"riseRate":0,"avgChangeRate":-0.340105},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.097481},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.081111},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.021473},{"month":7,"riseRate":0.666667,"avgChangeRate":0.642716},{"month":8,"riseRate":0,"avgChangeRate":-0.132338},{"month":9,"riseRate":0.666667,"avgChangeRate":-0.117003},{"month":10,"riseRate":0.25,"avgChangeRate":0.023682},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.089454},{"month":12,"riseRate":0.666667,"avgChangeRate":0.085781}],"exchange":"NASDAQ","name":"Neumora Therapeutics, Inc.","nameEN":"Neumora Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Neumora Therapeutics, Inc.(NMRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Neumora Therapeutics, Inc.(NMRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Neumora Therapeutics, Inc.,NMRA,Neumora Therapeutics, Inc.股票,Neumora Therapeutics, Inc.股票老虎,Neumora Therapeutics, Inc.股票老虎国际,Neumora Therapeutics, Inc.行情,Neumora Therapeutics, Inc.股票行情,Neumora Therapeutics, Inc.股价,Neumora Therapeutics, Inc.股市,Neumora Therapeutics, Inc.股票价格,Neumora Therapeutics, Inc.股票交易,Neumora Therapeutics, Inc.股票购买,Neumora Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Neumora Therapeutics, Inc.(NMRA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Neumora Therapeutics, Inc.(NMRA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}